Mantle Cell Lymphoma

Hun Ju Lee, MD, discusses the implications of phase I results regarding the combination of carfilzomib and ibrutinib in relapsed/refractory mantle cell lymphoma.

Reid W. Merryman, MD, discusses the impact of adding high-dose cytarabine to bendamustine and rituximab as an induction regimen for patients with mantle cell lymphoma.

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the rationale of the AIM trial in relapsed/refractory mantle cell lymphoma (MCL).

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Javier Munoz, MD, MS, FACP, discusses zanubrutinib’s path to approval in mantle cell lymphoma and its future potential.

Praveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

The FDA has granted a priority review designation to a biologics license application for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the immunologic impact of long-term venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the long-term immunological response to the combination of venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).